Bill Summary
This bill, known as the Transparency in Prescription Drug Advertising Act, would require the Secretary of Health and Human Services to issue guidance that requires pharmaceutical companies to include the list prices of their drugs in advertisements. This guidance must be issued within one year of the bill's enactment and will be developed in consultation with the Commissioner of Food and Drugs and the Administrator of the Centers for Medicare & Medicaid Services. The guidance must include enforcement mechanisms for companies who do not comply and should align with existing regulations related to drug pricing transparency.
Possible Impacts
1. This legislation could potentially affect pharmaceutical companies by requiring them to disclose the list prices of their drugs in all forms of advertising. This could impact their marketing strategies and potentially lead to changes in prices or discounts offered to consumers.
2. This legislation could also affect healthcare providers and insurance companies by providing more transparency in drug pricing. This could potentially lead to more informed decision making and negotiations for drug prices and coverage.
3. The legislation could also impact consumers by providing them with more information about the costs of drugs and potentially influencing their choices for medication based on price. It could also lead to increased awareness and advocacy for more affordable drug options.
[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5894 Introduced in House (IH)]
<DOC>
116th CONGRESS
2d Session
H. R. 5894
To direct the Secretary of Health and Human Services to issue guidance
requiring the list prices of drugs to be included in advertisements for
such drugs.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
February 13, 2020
Ms. Davids of Kansas (for herself, Ms. Slotkin, and Ms. Finkenauer)
introduced the following bill; which was referred to the Committee on
Energy and Commerce
_______________________________________________________________________
A BILL
To direct the Secretary of Health and Human Services to issue guidance
requiring the list prices of drugs to be included in advertisements for
such drugs.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Transparency in Prescription Drug
Advertising Act''.
SEC. 2. PRICING TRANSPARENCY IN DRUG ADVERTISING.
(a) In General.--Not later than one year after the date of
enactment of this Act, the Secretary of Health and Human Services, in
consultation with the Commissioner of Food and Drugs and the
Administrator of the Centers for Medicare & Medicaid Services, shall
issue department-wide guidance requiring the list prices of drugs to be
included, as appropriate, in all advertising of drugs, including by
means of television, newspapers, the internet, or other media.
(b) Enforcement; Consistency.--The guidance under subsection (a)--
(1) shall include appropriate enforcement mechanisms for
failure to make disclosures in accordance with the guidance;
and
(2) should be consistent with the regulation of the Centers
for Medicare & Medicaid Services related to drug pricing
transparency.
<all>